Drug-drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4

Bioelectrochemistry

Volumn 86, Issue , 2012, Pages 87-91

  Sadeghi, Sheila J ^a   Ferrero, Silvia ^a   Di Nardo, Giovanna ^a   Gilardi, Gianfranco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronoamperometry; Cytochrome P450; Glassy carbon; Inhibition; Protein immobilization

Indexed keywords

ADVERSE DRUG REACTIONS; BIOELECTROCHEMISTRY; CATIONIC POLYELECTROLYTE; COOPERATIVE EFFECTS; COOPERATIVITY; CYTOCHROME P450; CYTOCHROME P450-3A4; DICLOFENAC; DRUG METABOLISMS; DRUG-DRUG INTERACTIONS; GLASSY CARBON ELECTRODES; HUMAN CYTOCHROME; IN-VITRO; POLY (DIALLYLDIMETHYLAMMONIUM CHLORIDE); PROTEIN IMMOBILIZATION;

ANTIBIOTICS; BIOCHEMISTRY; CHLORINE COMPOUNDS; CHRONOAMPEROMETRY; ELECTROPHYSIOLOGY; ENZYME INHIBITION; GLASS MEMBRANE ELECTRODES; GLASSY CARBON;

DRUG INTERACTIONS;

CARBON; CIMETIDINE; CYTOCHROME P450 3A4; DICLOFENAC; ERYTHROMYCIN; KETOCONAZOLE; POLY(DIALLYLDIMETHYLAMMONIUM CHLORIDE); QUINIDINE;

AMPEROMETRY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ELECTROCHEMICAL DETECTION; ELECTRODE; ENZYME IMMOBILIZATION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HETEROTROPHY; IC 50; IN VITRO STUDY;

CIMETIDINE; CYTOCHROME P-450 CYP3A; DICLOFENAC; DRUG INTERACTIONS; ELECTROCHEMICAL TECHNIQUES; ELECTRODES; ENZYME INHIBITORS; ENZYMES, IMMOBILIZED; ERYTHROMYCIN; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; POLYETHYLENES; QUATERNARY AMMONIUM COMPOUNDS; QUINIDINE;

EID: 84860270945     PISSN: 15675394     EISSN: 1878562X     Source Type: Journal    
DOI: 10.1016/j.bioelechem.2012.02.010     Document Type: Article

References (32)

1. Friedman M.A., Woodcock J., Lumpkin M.M., Shuren J.E., Hass A.E., Thompson L.J. The safety of newly approved medicines: do recent market removals mean there is a problem?. JAMA: The Journal of the American Medical Association 1999, 281:1728-1734.
2. Issa A.M., Phillips K.A., Van Bebber S., Nidamarthy H.G., Lasser K.E., Haas J.S., Alldredge B.K., Wachter R.M., Bates D.W. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Current Drug Safety 2007, 2:177-185.
3. Wienkers L.C., Health T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews. Drug Discovery 2005, 4:825-833.
4. Ogilvie B.W., Usuki E., Yerino P., Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. Drug-Drug Interactions 2008, 231-358. Informa Healthcare, New York. A.D. Rodrigues (Ed.).
5. Atkins W.M. Non-Michaelis-Menten kinetics in cytochrome P450-catalysed reactions. Annual Review of Pharmacology and Toxicology 2005, 45:291-310.
6. Dodhia V.R., Gilardi G. Cytochromes P450: tayloring a class of enzymes for biosensing. Engineering the Bioelectronic Interface 2009, 154-193. RSC Publishing, London. J. Davis (Ed.).
7. Sadeghi S.J., Fantuzzi A., Gilardi G. Breakthrough in P450 bioelectrochemistry and future perspectives. Biochimica et Biophysica Acta 2011, 1814:237-248.
8. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450: Structure, Mechanism, and Biochemistry 2005, 377-530. Kluwer Academic/Plenum Press, New York. P.R. Ortiz de Montellano (Ed.).
9. Dodhia V.R., Fantuzzi A., Gilardi G. Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. Journal of Biological Inorganic Chemistry 2006, 11:903-916.
10. Nash T. The colourimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochemical Journal 1953, 55:416-421.
11. Dodhia V.R., Sassone C., Fantuzzi A., Di Nardo G., Sadeghi S.J., Gilardi G. Modulating the coupling efficiency of human cytochrome P450 3A4 at electrode surfaces through protein engineering. Electrochemistry Communications 2008, 10:1744-1746.
12. Léger C., Elliott S.J., Hoke K.R., Jeuken L.J.C., Jones A.K., Armstrong F.A. Enzyme electrokinetics: using protein film voltammetry to investigate redox enzymes and their mechanisms. Biochemistry 2003, 42:8653-8662.
13. Yano J.K., Wester M.R., Schoch G.A., Griffin K.J., Stout C.D., Johnson E.F. The structure of human cytochrome P450 3A4 determined by X-ray crystallography to 2.05Å resolution. Journal of Biological Chemistry 2004, 279:38091-38094.
14. Niwa T., Murayama N., Emoto C., Yamazaki H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Current Drug Metabolism 2008, 9:20-33.
15. Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 2008, 9:310-322.
16. Hianik T., Snejdárková M., Passechnik V.I., Rehák M., Babincová M. Immobilization of enzymes on lipid bilayers on a metal support allows study of the biophysical mechanisms of enzymatic reactions. Bioelectrochemistry and Bioenergetics 1996, 41:221-225.
17. Riley R.J., Howbrook D. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-C-14]-erythromycin. Journal of Pharmacological and Toxicological Methods 1997, 38:189-193.
18. Fantuzzi A., Fairhead M., Gilardi G. Direct electrochemistry of immobilized human cytochrome P450 2E1. Journal of the American Chemical Society 2004, 126:5040-5041.
19. Mak L.H., Sadeghi S.J., Fantuzzi A., Gilardi G. Control of human cytochrome P450 2E1 electrocatalytic response as a result of unique orientation on gold electrodes. Analytical Chemistry 2010, 82:5357-5362.
20. Panicco P., Dodhia V.R., Fantuzzi A., Gilardi G. Enzyme-based amperometric platform to determine the polymorphism response in drug metabolism by cytochromes P450. Analytical Chemistry 2011, 83:2179-2186.
21. Masubuchi Y., Ose A., Horie T. Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metabolism and Disposition 2002, 30:1143-1148.
22. Iwata H., Tezuka Y., Kadota S., Hiratsuka A., Watabe T. Identification and characterisation of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metabolism and Disposition 2004, 32:1351-1358.
23. Wrighton S.A., Ring B.J. Inhibition of human CYP3A catalysed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research 1994, 11:921-924.
24. Haehner T., Refaie M.O.I., Muller-Enoch D. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P450 3A4 and human NADPH-cytochrome P450 reductase system. Arzneimittelforschung - Drug Research 2004, 54:78-83.
25. Moody G.C., Griffin S.J., Mather A.N., McGinnity D.F., Riley R.J. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999, 29:53-75.
26. Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. The FASEB Journal 1992, 6:752-758.
27. Ngui J.S., Tang W., Stearns R.A., Shou M., Miller R.R., Zhang Y., Lin J.H., Baillie T.A. Cytochrome P450 3A4-mediated interactions of diclofenac and quinidine. Drug Metabolism and Disposition 2000, 28:1043-1050.
28. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., Tracey T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochromes P450 active sites. Biochemistry 1998, 37:4137-4147.
29. Shou M., Dai R., Korzekwa K.R., Baillie T.A., Rushmore T.H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. Journal of Biological Chemistry 2001, 276:2256-2262.
30. Domanski T.L., He Y.A., Khan K.K., Rousel F., Wang Q., Halpert J.R. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001, 40:10150-10160.
31. Ekroos M., Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proceedings of the National Academy Sciences 2006, 103:13682-13687.
32. Yang M., Kabulski J.L., Wollenberg L., Chen X., Subramanian M., Tracy T.S., Lederman D., Gannett P.M., Wu N. Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode. Drug Metabolism and Disposition 2009, 37:892-899.